Alonso, RafaelCedena, María TeresaGómez-Grande, AdolfoRíos, RafaelMoraleda, José MaríaCabañas, ValentínMoreno, María JoséLópez-Jiménez, JavierMartín, FernandoSanz, AlejandroValeri, AntonioJiménez, AnaSánchez, RicardoLahuerta, Juan JoséMartínez-López, Joaquín2023-01-252023-01-252019-06-09http://hdl.handle.net/10668/13936The value of minimal residual disease (MRD) status by bone marrow and imaging analysis as independent prognostic factors has been well established in multiple myeloma (MM). Nevertheless data about their potential complementarity for a more accurate assessment are limited. With this aim, we retrospectively analyzed the prediction of outcome with the combination of PET-CT and MRD, assessed by multiparameter flow cytometry (MFC) in 103 patients with newly diagnosed MM. We confirmed the benefit in terms of progression-free survival (PFS), linked to the achievement of negativity by MFC (hazard ratio [HR] 0.53; 95% confidence interval [CI]: 0.28-0.98), and PET-CT (HR 0.18; 95% CI: 0.09-0.36) individually. By combining both techniques, patients who became MRD-/PET-, with a median of PFS 92 months, had significant prolonged median PFS (PenBone MarrowFlow CytometryHumansKaplan-Meier EstimateMultiple MyelomaNeoplasm, ResidualPositron Emission Tomography Computed TomographyProgression-Free SurvivalProportional Hazards ModelsRetrospective StudiesWhole Body Imagingresearch article31074033open access10.1002/ajh.255071096-8652https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25507